ResearchMoz

Pharmaceutical Industry in China Q3 2013 - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

Kelly Scientific Publications
Published Date » 2013-11-01
No. Of Pages » 145
 
   
 This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.  
   
 The Chinese Pharmaceutical market is currently the third greatest pharma market globally, after the US and Japan, and in 2011 was worth $x. It is forecast to increase dramatically to $x by 2015 and increase its dominance as a leading player in Asia. As the current third market leader it is predicted that the Chinese pharma market will be the main competitor of the US by 2020.  
   
 This report describes the current therapeutics that are propelling the biopharmaceutical market in China. It examines the...
TABLE OF CONTENT

1.0 Summary   8
1.1 Objectives of Report  8
1.2 Scope of Study   9
1.3 Data Sources and Methodology 10
1.4 Key Findings and Observations 10
1.5 Executive Summary  11

2.0 Chronic Disease Prevalence Statistics 14

3.0 Business Environment  16
3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 16
3.2 Gross Domestic Product of China, Historic and Projection Analysis   18
3.3 Annual Health Expenditure in China, Historic and Projected Analysis   19
3.4 Global and Chinese Economic Outlook 2010-2013 20
3.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries 21
3.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe) 23

4.0 Chinese Pharmaceutical Market 28
4.1 Market Overview  28
4.2 Main Players in China’s Pharmaceutical Industry 31
4.3 Anti-Allergy Drug Market 31
4.4 Asthma Drug Market  32
4.5 Benign Prostate Hyperplasia Drug Market 32
4.6 Anti-Depressant Drug market 33
4.7 Dermatitis  Drug Market 35
4.8 Diabetes Drug Market  36
4.9 Hypertension Drug Market 37
4.10 Dyslipidaemia Drug Market 38
4.11 Senile Dementia Drug Market 39
4.12 Cancer Drug Market  40
4.13 Rheumatoid Arthritis Drug Market 40
4.14 Ophthalmological Drug Market 41
4.15 Liver Disease Drug Market 43
4.16 Antibiotic Drug Market  44

5.0 Government and Regulation Environment 45
5.1 12th Five Year Plan  45
5.2 Intellectual Property for Pharmaceuticals in China 47
5.3 State Food and Drug Administration (SFDA) 52
5.4 Pharmaceutical Distribution Process in China 55

6.0 China – Third Largest Pharma Market 2012 58
6.1 China – At the Forefront of Emerging Markets 58
6.2 Generic Medication Market and China 58
6.3 Novel Product Drug Development 60
6.4 Drug Development Cost and Outsourcing 62
6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals   63
6.6 China’s Pharmaceutical Export Market 63
6.7 Spot Light - China Medical City Taizhou 65

7.0 Global Pharmaceutical Companies Interest in China 67
7.1 Abbott China   67
7.2 AstraZeneca China   75
7.3 Bayer China   83
7.4 Boehringer Ingelheim China  87
7.5 Eli Lilly China 89
7.6 GlaxoSmithKline China  91
7.7 Johnson & Johnson Medical China 96
7.8 Merck China   100
7.9 Novartis China 102
7.10 Novo Nordisk China  105
7.11 Pfizer China   108
7.11.1 Pfizer China R&D Centre 110
7.11.2 Pfizer China Products  110
7.11.3 Pfizer Financials  113
7.11.4 Pfizer Global   114
7.12 Roche China   114
7.13 Sanofi China   120

8.0 Chinese Pharmaceutical Companies 123
8.1 Amoytop Biotech  123
8.2 Active Pharmaceutical Products  125
8.2.1 Research and Development 126
8.2.2 Financial Information  126
8.3 Beijing Continent Pharmaceuticals 126
8.4 FusoGen Pharmaceuticals 127
8.4.1 Financial Information  128
8.5 Shanghai Huaguan Biochip 128
8.5.1 Financial Information  131
8.6 SiBiono GeneTech  131
8.6.1 Financial Information  132
8.7 Sinovac Biotech  132
8.7.1 Financial Information  134
8.7.2 New Products 139
8.7.3 Split Virion Pandemic Influenza Vaccine 139
8.7.4 RabEnd 139
8.7.5 Pipeline Portfolio  139
8.7.6 EV71 virus Vaccine  139
8.7.7 Pneumococcal Conjugate Vaccine 140
8.7.8 Pneumococcal Polysaccharide Vaccine 140
8.7.9 Varicella Vaccine   140
8.7.10 Measles, Mumps and Rubella Vaccines 140
8.7.11 Rotavirus Vaccine  140

9.0 Drivers, Restraints, Challenges and Opportunity Analysis 141
9.1 Key Drivers of the Pharmaceutical Market in China 141
9.2 Key Restraints of the Pharmaceutical Market in China 142
9.3 Challenges of the Pharmaceutical Industry in China 143
9.4 Opportunities Within BioPharma China 145

List of Tables


Table 2.1: Most Prominent Cancer Manifestations in China 15
Table 2.2: Top Fifty Diseases in China Today (non-cancer) 15
Table 2.3: Top Infectious Disease States in China Today 15
Table 3.1: World Trade Organisation Basic Indicators on China 16
Table 3.2: World Trade Organisation Trade Policy of China 16
Table 3.3: World Trade Organisation Merchandise Trade Statistics: China   17
Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China  17
Table 3.5: Summary of International Monetary Fund Members’ Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China  18
Table 3.6: China Statistics  18
Table 4.1: Top Global Pharma Markets 2003-2013 28
Table 4.2: Major Players in China’s Anti-Allergy Drug Market 31
Table 4.3: Major Players in China’s Asthma Drug Market 32
Table 4.4: Major Players in China’s Benign Prostate Hyperplasia (BPH) Drug Market  33
Table 4.5: Major Players in China’s Anti-Depressant Drug Market 34
Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics 35
Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market 35
Table 4.8: Major Players in China’s Dermatitis Drug Market 35
Table 4.9: Major Players in China’s Diabetic Drug Market 37
Table 4.10: Major Players in China’s Hypertension Drug Market 38
Table 4.11: Major Players in China’s Dyslipidaemia Drug Market 38
Table 4.12: Major Players in China’s Senile Dementia Drug Market 39
Table 4.13: Major Players in China’s Cancer Drug Market 40
Table 4.14: Major Players in China’s Rheumatoid Arthritis Drug Market 41
Table 4.15: Major Players in China’s Ophthalmological Drug Market 42
Table 4.16: Major Players in China’s Liver Disease Drug Market 43
Table 4.17: Major Players in China’s Antibiotic Drug Market 44
Table 5.1: Seven Strategic Emerging Industries of China’s 12th Five Year Plan 2011-2015  45
Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012   47
Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China   55
Table 5.4: Prescription Drug Sales Distribution Channels in China 55
Table 6.1: Major Biogeneric Products in China 59
Table 6.2: Imported Therapeutics with Administrative Protection in China   59
Table 6.3: Expired Proprietary Pharmaceuticals in China 60
Table 6.4: Reasons Why Multinational Companies Seek CMO’s in China 62
Table 6.5: Comparison of Clinical Trial Cost between China and the USA   63
Table 6.6: Five Functional Districts of China Medical City 65
Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City   66
Table 7.1: Top Multinational Company Performance, China 67
Table 7.2: Abbott Areas of Expertise 69
Table 7.3: Abbott Key Global Products 71
Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions  71
Table 7.5: Abbott China Anaesthesia Product Profile 71
Table 7.6: Abbott China Cardiovascular Product Profile 72
Table 7.7: Abbott China Vaccine Product Profile 72
Table 7.8: Abbott China Digestion Product Profile 72
Table 7.9: Abbott China HIV Product Profile 72
Table 7.10: Abbott Rheumatology HIV Product Profile 72
Table 7.11 Abbott China Gynaecological Product Profile 72
Table 7.12 Abbott China Urological Product Profile 72
Table 7.13 Abbott China Liver Disease Product Profile 73
Table 7.14 Abbott China Diagnostic Product Profile 73
Table 7.15: Abbott China Molecular Diagnostic Product Profile 73
Table 7.16: Abbott Blood Glucose Meter Product Profile 74
Table 7.17: Abbott Cardiovascular Product Profile 74
Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile   74
Table 7.19: Important Milestones in AstraZeneca China’s History 75
Table 7.20: AstraZeneca China Anaesthetic Range of Products 76
Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products  76
Table 7.22: AstraZeneca China Gastrointestinal Range of Products 76
Table 7.23: AstraZeneca China Infection Range of Products 76
Table 7.24: AstraZeneca China Neurology Range of Products 76
Table 7.25: AstraZeneca China Oncology Range of Products 77
Table 7.26: AstraZeneca China Respiratory Range of Products 77
Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 2012 79
Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally 2010-2012  79
Table 7.29: Bayer China Important Milestones 84
Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China  85
Table 7.31: Bayer - Leading Therapeutics in China 86
Table 7.32: Bayer Top Selling Consumer Health Products 86
Table 7.33: Boehringer Ingelheim Major Products in China 87
Table 7.34: Main Therapeutic Areas of Interest to Boehringer Ingelheim China   87
Table 7.35: Global Therapeutic Pipeline, Boehringer Ingelheim 88
Table 7.36: Major Global Boehringer Ingelheim Therapeutic Products 88
Table 7.37: GlaxoSmithKline Prescription Portfolio and Indications in China   91
Table 7.38: GlaxoSmithKline Vaccine Portfolio and Indications in China 92
Table 7.39: GlaxoSmithKline Over the Counter Portfolio and Indications in China  92
Table 7.40: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012  94
Table 7.41: GlaxoSmithKline Global Vaccine Sales 2012 95
Table 7.42: Significant Milestones in Johnson and Johnson China History   96
Table 7.43: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area and Percentage Change, 2012  99
Table 7.44: Merck Serono Pharmaceutical Key Therapeutic Areas in China   100
Table 7.45: Merck Serono Fertility and Infertility Therapeutic Portfolio in China   100
Table 7.46: Merck Serono Therapeutic Portfolio in China 101
Table 7.47: Merck Pharmaceutical Hong Kong Therapeutic Portfolio 101
Table 7.48: Range of Diabetic Products from Novo Nordisk China 106
Table 7.49: QUICKFACTs - Pfizer China 109
Table 7.50: Important Milestones – Pfizer China 109
Table 7.51: Pfizer China – Range of Infectious Disease Therapeutics for Chinese Health Care Market 110
Table 7.52: Pfizer China – Range of  Mental Health Products for Chinese Health Care Market  111
Table 7.53: Pfizer China – Range of Genitourinary Products for Chinese Health Care Market  111
Table 7.54: Pfizer China – Range of Endocrine Products for Chinese Health Care Market  111
Table 7.55: Pfizer China – Range of Women’s Health Products for Chinese Health Care Market  111
Table 7.56: Pfizer China – Range of Cardiovascular Disease Products for Chinese Health Care Market 111
Table 7.57: Pfizer China – Range of Oncology Products for Chinese Health Care Market  111
Table 7.58: Pfizer – Key Consumer Healthcare Global Products 112
Table 7.59: Pfizer – Key Speciality Care Global Products 112
Table 7.60: Pfizer – Key Oncology Global Products 112
Table 7.61: Pfizer – Key Global Established Products 112
Table 7.62: Pfizer – Key Innovative Products in Emerging Markets 112
Table 7.63: Pfizer – Key Animal Health Global Products 113
Table 7.64: Pfizer Product Sales with Significant Impact on Revenues 2011:2012 Comparison 113
Table 7.65: Roche Pharmaceuticals Product List in China 115
Table 7.66: Roche Global Sales (CHF Millions) by Therapeutic Area, 2011, 2012 and Percentage Change (CER) 117
Table 7.67: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011, 2012 and Percentage Change (CER) 118
Table 7.68: Seven Growth Platforms of Sanofi China 120
Table 7.69: Key Therapeutic Areas of Sanofi China 120
Table 8.1: Important Milestones in Amoytop Biotech’s Development 123
Table 8.2: Amoytop Biotech – Main Objectives of Research and Development Division  124
Table 8.3: Amoytop Biotech – Panel of Recombinant Protein Therapeutics in Clinical Studies  124
Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China 125
Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech   125
Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech 125
Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals 128
Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals   128
Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio 129
Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile   129
Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio 129
Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio 129
Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio 130
Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech 131
Table 8.15: Gendicine - Potential Oncology Indications for Future Approval   132
Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech 133
Table 8.17: Important Milestones in the History of Sinovac Biotech 133
Table 8.18: Pipeline Portfolio of Sinovac Biotech 133
Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012 135
Table 9.1: Key Drivers of the Pharmaceutical Market in China 141
Table 9.2: Key Restraints of the Pharmaceutical Market in China 142
Table 9.3: Key Challenges of the Pharmaceutical Market in China 143
Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020   144
Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China   145

List of Figures


Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages   14
Figure 3.1: China GDP Figures 2006-2015 19
Figure 3.2: Annual Health Expenditure in China 2006-2015 19
Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013 20
Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013 21
Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 2010-2013 22
Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013 22
Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 23
Figure 3.8: Global, US and Germany Economic Growth 2010-2013 24
Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017   24
Figure 3.10: Global, France and Italy Economic Growth 2010-2013 25
Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017  25
Figure 3.12: Global, UK and Spain Economic Growth 2010-2013 26
Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013 26
Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017 27
Figure 4.1: The Chinese Healthcare Industry by Sector, 2011 30
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution 2011-2020 46
Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs 53
Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials 54
Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market  56
Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market  56
Figure 6.1: Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth  58
Figure 6.2: Number of Investigational New Drug Applications in China 2003-2010  60
Figure 6.3: Number of New Drug Applications in China 2003-2010 61
Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China  61
Figure 6.5: Percentage of Clinical Trial Drug by Disease State 62
Figure 6.6: China’s Regional Pharmaceutical Processing Trade Export Market Share Percentage   64
Figure 6.7: Contract Amount of China’s Regional Pharmaceutical Processing Trade Export 64
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China 65
Figure 7.1: Abbott Laboratories Geographic Distribution of Revenue –USA, Established and Emerging Markets   68
Figure 7.2: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015 69
Figure 7.3: Abbott – Business Specialization Strategy 2012: Diversified Medical Products and Research-Based Pharmaceuticals 70
Figure 7.4: Abbott Diversified Medical Product Portfolio 70
Figure 7.5: AstraZeneca Sales Revenue (US$ Millions) in China, 2010-2012   78
Figure 7.6: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Western Europe, Emerging Markets 2012   78
Figure 7.7: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales 2010-2012 80
Figure 7.8: AstraZeneca Gastrointestinal Product (Nexium) Global Sales 2010-2012  80
Figure 7.9: AstraZeneca Infection Product (Synagis) Global Sales 2010-2012   81
Figure 7.10: AstraZeneca Neuroscience Product (Seroquel-IR, -XR) Global Sales 2010-2012 81
Figure 7.11: AstraZeneca Oncology Product (Zoladex) Global Sales 2010-2012   82
Figure 7.12: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012 82
Figure 7.13: Boehringer Ingelheim Oncology Compounds in Development   89
Figure 7.14: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012 (£ Billions)   93
Figure 7.15: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012  94
Figure 7.16: GlaxoSmithKline Global Vaccine Sales by Therapeutic Area, 2012   95
Figure 7.17: GlaxoSmithKline Global Sales by Geographic Region – USA, Europe, Emerging Markets, Japan, 2012   96
Figure 7.18: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 2012  99
Figure 7.19: Novartis International Sales (%) by Geographic Region, 2012   104
Figure 7.20: Novartis International Sales (US$ Millions) by Geographic Region, 2012  104
Figure 7.21: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China 2010-2012 107
Figure 7.22: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China 2010-2012 108
Figure 7.23: Business Sectors – Pfizer China 110
Figure 7.24: Roche Total Global Sales (CHF Millions) 2011, 2012 117
Figure 7.25: Roche Global Sales (CHF Millions) by Therapeutic Area, 2011, 2012  118
Figure 7.26: Roche Pharmaceutical Division Emerging Market Total Sales 2011, 2012  119
Figure 7.27: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011, 2012  119
Figure 7.28: Sanofi Geographic Market Share (%) – Emerging Markets, USA and Western Europe 2012  121
Figure 7.29: Sanofi Geographic Market Share (%) –China, Russia and USA 2012   122
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression  127
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service 130
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012 135
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012   136
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012 136
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012 137
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012 138
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011 138

Upcoming Reports:

Blood Glucose Test Strips Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Blood glucose or blood sugar refers to the sugar passed through the blood stream that is responsible for ensuring the energy supply to all the cells in the body. The regulation of blood glucose levels is essential in order to maintain the normal levels thereby maintaining hemostasis (maintaining a stable or equilibrium condition in the blood’s internal environment). The state of hemostasis is necessary for our bodies to ensure proper functionality.  There exist different types of blood glucose measurement tests performed such as fasting blood sugar test,...
Hydrographic Equipment Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Hydrographic survey is a process used to measure and describe the bodily features of oceans, seas coastal areas, lakes and rivers. The equipments which are required to do such surveys are known as hydrographic equipments. The main goal of hydrographic surveys is to ensure safe maritime navigation. Sometimes the term hydrographic surveys and maritime cartography are used synonymously; however maritime cartography is the final process of hydrographic surveys and is used to convert the raw data collected in hydrographic surveys to pull out some useful information. Hydrographic surveys are...
Poland: market of electric instantaneous water heaters
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the electric instantaneous water heaters market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the electric instantaneous water heaters market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way,...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Does Chewing Gum Lead to Academic Productivity?
Aug 20, 2014  
Could chewing gum actually lead to improved academic productivity? A study conducted recently has found that there may possibly be a link between the two, finally making some headway in a decade-old research. The study called ‘The Effects of Gum Chewing on Math Scores in Adolescents’ was led by Craig Johnston from Baylor College of Medicine in Houston, Texas, and was sponsored by...
German Arms Industrys Outlook Uncertain
Aug 20, 2014  
During a recent meeting between representatives of the German ammunition and arms industry and the German Ministry for Economic Affairs, the unionists discussed concerns about the declining approvals for German arms shipment contracts. Workers’ representatives had, earlier in July 2014, written to the German minister of economic affairs Sigmar Gabriel stating that these curbs on...
Microcontrollers Market Poised to Witness Full-Blown Recovery
Aug 20, 2014  
The microcontrollers industry may well be on the verge of a full-blown recovery thanks to a rebound in sales to automotive and industrial customers. Analysts say that this recovery isn’t limited to the 32-bit market. Signs of growth are also being seen in the 8-bit industry, with a higher inflow of new orders.  The growth has been so encouraging that Arizona-based Microchip...
US Vessel Cape Ray Destroyed Syrias Chemical Weapons
Aug 19, 2014  
RIA Novosti, Monday news stated that teams aboard the MV Cape Ray (US vessel) have completed the task of neutralizing the chemical stockpile materials declared in Syria. This was informed by John Kirby, Pentagon Press Secretary Rear Adm. The Secretary of Defense – Chuck Hagel congratulated the Navy Captain – Rich Dromerhauser ship's crew on completing their task of...
Surge in Bourbon Production
Aug 19, 2014  
America’s bourbon whiskey manufacturer, Kentucky, has taken a decision on hoarding large stockpiles of bourbon whiskey. According to sources, distillers are stocking up the huge quantities of bourbon even before the demand for the same has arisen in the market.  This step of excess production involves a certain risk, but as soon as the market demand for this dominates the...